ClinicalTrials.gg
CompletedNCT04769869Updated Mar 20, 2023

A Clinical Trial in Healthy Volunteers and Patients With Mild Asthma to Investigate a New Medicine (AZD4604) for the Treatment of Asthma

A Phase 1 interventional study of AZD4604 for inhalation via DPI and Placebo for AZD4604 for inhalation via DPI in Asthma, sponsored by AstraZeneca. Completed at 3 sites in United Kingdom. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-03-20.

Sponsored by AstraZeneca · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
110
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 359 studies in Asthma by AstraZeneca — 19 open to participants now, 28 under way, 8 of them phase 3. Asthma · AstraZeneca.

Enrollment
146th of 248
110 · median 175
Started
2022
with 12 others
Phase 1
46 of 359
none open now
Registered
275th of 359
by date

Among the 359 studies in Asthma by AstraZeneca, this one is the 146th largest by enrollment of the 248 interventional ones that give a count, is one of 13 that started in 2022, is one of 46 in phase 1, and was the 275th registered.

Asthma

4,848 studies on the registry are indexed under Asthma; 603 are open to participants now.

Browse Asthma studies →

Open to participants now

19 of the 359 studies in Asthma by AstraZeneca are open now, in 12 countries. Recruiting first, the newest first:

14 more — sign in →

By country, each count listing its studies:

All 19 open studies →

Who these studies take

Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 359 studies in Asthma by AstraZeneca, or all of them as a file.
02

Study summary

This is a first in human clinical study. Part 1 of the clinical study will assess the safety and tolerability, as well as the single dose pharmacokinetics (PK), of inhaled AZD4604 in healthy volunteers (Part 1a, single ascending dose [SAD]). The single dose administration will be performed with dry powder inhaler (DPI) formulation of AZD4604. When at least 4 cohorts of the SAD part of the study have been completed, AZD4604 will be administered as a single intravenous (IV) or oral (PO) dose to 2 different cohorts of healthy volunteers (Part 1b). The main purpose is to compare the PK between IV, oral and inhaled administration to further characterize the PK properties of AZD4604 by the various administration routes. The results will be used to improve future study design and interpretation. In Part 2 (Multiple ascending dose [MAD]), AZD4604 will be administered at multiple doses (twice daily [BID], 7 days) to healthy volunteers. In Part 3, AZD4604 will be administered at multiple doses to patients with mild asthma at dose levels assessed in Part 2. The multiple-dose administration will be performed with DPI-formulated AZD4604.

Read the detailed description

Part 1a of the study will be a randomized, single-blind, placebo-controlled, SAD, sequential group design study. Seven inhaled dose levels of AZD4604 are planned to be investigated in cohorts of 8 healthy volunteers, with 6 healthy volunteers randomly assigned to inhaled AZD4604 and 2 healthy volunteers randomly assigned to inhaled placebo in each cohort.

Part 1a will comprise of:

  • A Screening Visit within 28 days before dosing.
  • A Treatment Period (Day -1 to Day 7, in the Clinical Unit) with a single inhaled dose of AZD4604 or corresponding placebo on Day 1. Although the anticipated systemic exposure and risk for potential adverse systemic effects are considered to be low for AZD4604, healthy volunteers will remain resident at site for additional 6 days of monitoring.
  • A Final Assessment on day of discharge.

In Part 1b, AZD4604 will be administered as a single IV or a PO dose to healthy volunteers in order to compare the PK between IV, PO and inhaled administration. Part 1b will be open-label and consist of 2 dose cohorts, IV and PO, with 6 healthy volunteers in each.

Part 1b will comprise of:

  • A washout period of at least 2 weeks for the healthy volunteers who received inhaled dosing in Part 1a will occur before IV or PO dosing in Part 1b. All healthy volunteers will have a Screening Visit within 28 days of dosing.
  • A Treatment Period (Day -1 to Day 3, in the Clinical Unit) with a single IV or PO dose of AZD4604 on Day 1.
  • A Follow-up Visit within 6 ± 1 day after dosing.

Part 2 of the study will be a randomized, single-blind, placebo-controlled, MAD, sequential group design. This part of the study will be conducted in up to 32 healthy volunteers.

Part 2 will comprise of:

  • A Screening Visit within 28 days before first dosing.
  • A Treatment Period (Day -1 to Day 12 in the Clinical Unit) with twice daily (BID) inhaled doses of AZD4604 or placebo on Day 1 to Day 6 (12-hour [+/- 30 minutes] intervals between doses), and a single inhaled dose on Day 7. The healthy volunteers will remain resident at site for additional 6 days of monitoring, which is predicted to allow sufficient time for near complete washout (estimated time for > 97% of the dose to have been eliminated) of any target engagement from the lungs. Healthy volunteers will remain in the Clinical Unit for the duration of the treatment period and will be discharged on Day 13, 6 days after administration of the last dose.
  • A Final Assessment on day of discharge.

Part 3 of the study will be a randomized, single-blind, placebo-controlled, multiple-dose, PK and pharmacodynamic (PD) study part, with daily non-residential visits during the Treatment Period. This part of the study will be conducted in at least 45 patients with mild asthma (16 patients in Cohorts 1 and 2 and at least 29 patients in the Proof of Mechanism [PoM] Cohort).

Part 3 will comprise of:

  • A Screening Visit within 42 days before first dosing.
  • A Treatment Period (Day -3 to Day 15 as daily non-residential visits) with BID inhaled doses of AZD4604 or placebo on Day 1 to Day 9 (12-hour intervals between doses), and a single inhaled dose on Day 10. Dosing will take place at the clinical site and patients will need to visit the site twice daily on Day 1 to Day 9. The anticipated systemic exposure and risk for potential adverse systemic effects are considered to be low for AZD4604, therefore, patients will not be required to be resident at site during the Treatment Period.
  • A Final Assessment (Day 16) on the last day of the Treatment Period.
03

Conditions studied

  • Asthma

Browse trials for

Keywords

  • AZD4604
  • Placebo-controlled
  • Pharmacokinetics
  • First in Human
  • Single Ascending Dose
  • Multiple Ascending Dose
  • Inhaled Janus Kinase (JAK) Inhibitor
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

All Study Parts:

  • Provision of signed and dated, written prior to any study specific procedures.
  • Female subjects must have a negative pregnancy test at the Screening Visit and on admission to the Study Center or prior to randomization for Part 3 (Day -1 or Day 1 visit) and must not be lactating. Women of non-, must fulfill one of the following criteria:

    • defined as amenorrhea for at least 12 months or more following cessation of all exogenous hormonal treatments and follicle stimulating hormone levels in the postmenopausal range.
    • Documentation of irreversible surgical sterilization by hysterectomy, bilateral oophorectomy or bilateral salpingectomy but not bilateral tubal ligation.
  • Male subjects and their Women of childbearing potential (WOCBP) partners should be willing to use highly effective measures and should refrain from donating sperm or fathering a child from the first day of dosing until 3 months after the last dose of medicinal product (IMP).
  • WOCBP must be willing to use highly effective contraception measures from the first day of dosing until at least 1 month after the last dose of IMP, such as measures that results in low failure rate, ie, less than 1% per year.

Part 1a, Part 1b, and Part 2 Only:

  • Healthy male and female (including WOCBP) volunteers aged 18 to 55 years with suitable veins for cannulation or repeated venipuncture.
  • Have a between 18 and 30 kg/m2 inclusive and weigh at least 60 kg.

Part 1a and Part 2 Only:

  • Healthy volunteers must have a ≥ 80% of the predicted value regarding age, height, gender and ethnicity at the Screening and the Randomization Visits in accordance with American Thoracic Society (ATS)/ European Respiratory Society (ERS) criteria.

Part 3 Only:

  • Male and female (including WOCBP) patients with mild asthma aged 18 to 65 years with suitable veins for cannulation or repeated venipuncture.
  • Have a BMI between 18 and 35 kg/m2 inclusive and weigh at least 60 kg.
  • Physician diagnosed mild asthma for at least 6 months prior to Screening Visit.
  • Lung function ≥ 70% predicted for FEV1 at the Screening Visit AND on pre-morning dose Day -1, in accordance with the ATS/ERS criteria.
  • Have a FeNO of ≥ 40 ppb at the Screening Visit and at the corresponding clock-time of pre-morning dose on Day-3.
  • Must have evidence of up-to-date Coronavirus disease 2019 (COVID-19) vaccination status as per local guidelines.

Exclusion criteria

Exclusion criteria:

All Study Parts:

  • History of any disease or disorder.
  • Subject has an increased risk of infection.
  • History of cancer within the last 10 years except for basal and squamous cell carcinoma of the skin or in situ carcinoma of the cervix treated and considered cured.
  • Disease history suggesting abnormal immune function.
  • Have received any vaccine in the 30 days prior to the first dose.
  • Has a body temperature of > 37.7°C on Day-1.
  • History or presence of gastrointestinal, hepatic or renal disease.
  • Any clinically important illness, medical/surgical procedure, or trauma within 4 weeks of the first administration of medicinal product (IMP).
  • High-sensitivity C-reactive protein > (ULN) at Screening Visit and on Day -1.
  • Any clinically important abnormalities in clinical chemistry, hematology or urinalysis results. Consider appropriate ethnicity adjusted local reference ranges for hematology measurements, when available.
  • Abnormal vital signs at the Screening Visit, after 5 minutes supine rest.
  • Known or suspected history of drug abuse.
  • Current smokers or those who have smoked or used nicotine products.
  • History of alcohol abuse or excessive intake of alcohol.
  • Positive screen for drugs of abuse or cotinine (nicotine).
  • History of severe allergy/ or ongoing clinically important allergy/hypersensitivity, or history of hypersensitivity to drugs with a similar chemical structure or class to AZD4604.
  • Excessive intake of caffeine containing drinks or food (eg, coffee, tea, chocolate).
  • Use of drugs with enzyme inducing properties such as St John's Wort within 3 weeks prior to the first administration of investigational medicinal product.
  • Plasma donation within one month of the Screening Visit or any blood donation/blood loss > 500 mL during the 3 months prior to the Screening Visit.
  • Has received another new chemical entity (defined as a compound which has not been approved for marketing) within 3 months of the first administration of IMP in this study.
  • Involvement of any AstraZeneca or study Center employee or their close relatives.
  • Subject should not participate in the study if they have any ongoing or recent minor medical complaints that may interfere with the interpretation of study data.
  • Subjects who cannot communicate reliably.
  • Vulnerable subjects.
  • Any clinically important abnormalities in rhythm, conduction or morphology of the resting (ECG) and any clinically important abnormalities in the 12 lead ECG that may interfere with the interpretation of changes, including abnormal ST T wave morphology, particularly in the clinical study protocol (CSP) defined primary lead or left ventricular hypertrophy.
  • Female subjects who are planning a pregnancy during the study period or within 1 month after the last dose of IMP.

Part 1a, Part 1b, and Part 2 Only:

  • Any laboratory values with the deviations at the Screening Visit and on Day 1.
  • Persistent or intermittent complete Bundle branch block (BBB), Incomplete bundle branch block (IBBB), or Intraventricular conduction delay (IVCD) with ECG interval measured from the onset of the QRS complex to the J point (QRS) > 110 ms.
  • Subjects who have medical dietary restrictions or dietary restrictions which the site are unable to cater for.
  • Use of any prescribed or nonprescribed medication during the 2 weeks prior to the first administration of IMP or longer if the medication has a long half life.
  • History of any respiratory disorders.
  • Clinically significant history of allergic rhinitis/hay fever or anaphylaxis.

Part 3 Only:

  • Exacerbation of asthma symptoms and requiring the use of oral or IV , antibiotics, Accident and Emergency visit, or hospital admission.
  • Any laboratory values with the deviations at the Screening Visit and on Day -1. Abnormal values may be repeated once at the discretion of the PI: (a) > 1.25 × upper-limit of normal (ULN); (b)Aspartate aminotransferase > 1.25 × ULN; (c)Total > 1.25 × ULN; (d) Creatinine > ULN; (e) \< lower limit of normal (LLN) at the Screening Visit; (f) Absolute lymphocyte count \< LLN at the Screening Visit; (g) \< LLN
  • Persistent or intermittent complete BBB, IBBB, or IVCD with QRS > 110 ms. Patients with IVCD and QRS \<120 ms are acceptable if there is no evidence of eg, ventricular hypertrophy or pre-excitation.
  • Use of the following medicines before Screening Visit: Long-acting β2 agonists; Biologics for asthma; Inhaled corticosteroids (ICS) > 500 μg per day of beclometasone dipropionate or equivalent; Any ICS at any dose; Oral or injectable steroids for treatment of asthma or respiratory tract infection; Intranasal steroids; Leukotriene antagonists; Xanthines (excluding caffeine), anticholinergics, or cromoglycate; Short-acting bronchodilator other than for rescue.
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Single (Participant)
Enrollment
110 participants (actual)

Study arms

  • Experimental
    Part 1a (SAD): AZD4604 for inhalation via DPI (Dose 1)

    Healthy volunteers will receive a single inhaled dose of AZD4604 Dose 1 administered with a DPI.

    Drug: AZD4604 for inhalation via DPI

  • Experimental
    Part 1a (SAD): AZD4604 for inhalation via DPI (Dose 2)

    Healthy volunteers will receive a single inhaled dose of AZD4604 Dose 2 administered with a DPI.

    Drug: AZD4604 for inhalation via DPI

  • Experimental
    Part 1a (SAD): AZD4604 for inhalation via DPI(Dose 3)

    Healthy volunteers will receive a single inhaled dose of AZD4604 Dose 3 administered with a DPI.

    Drug: AZD4604 for inhalation via DPI

  • Experimental
    Part 1a (SAD): AZD4604 for inhalation via DPI (Dose 4)

    Healthy volunteers will receive a single inhaled dose of AZD4604 Dose 4 administered with a DPI.

    Drug: AZD4604 for inhalation via DPI

  • Experimental
    Part 1a (SAD): AZD4604 for inhalation via DPI (Dose 5)

    Healthy volunteers will receive a single inhaled dose of AZD4604 Dose 5 administered with a DPI.

    Drug: AZD4604 for inhalation via DPI

  • Experimental
    Part 1a (SAD): AZD4604 for inhalation via DPI (Dose 6)

    Healthy volunteers will receive a single inhaled dose of AZD4604 Dose 6 administered with a DPI.

    Drug: AZD4604 for inhalation via DPI

  • Experimental
    Part 1a (SAD): AZD4604 for inhalation via DPI (Dose 7)

    Healthy volunteers will receive a single inhaled dose of AZD4604 Dose 7 administered with a DPI.

    Drug: AZD4604 for inhalation via DPI

  • Experimental
    Part 1a (SAD): AZD4604 for inhalation via DPI

    An additional cohort of healthy volunteers will receive a single inhaled dose of AZD4604 administered with a DPI.

    Drug: AZD4604 for inhalation via DPI

  • Placebo comparator
    Part 1a (SAD): Placebo for AZD4604 for inhalation via DPI

    Healthy volunteers will receive placebo administered with a DPI.

    Drug: Placebo for AZD4604 for inhalation via DPI

  • Experimental
    Part 1b: AZD4604 for intravenous administration

    Healthy volunteers will receive a single IV dose of AZD4604 administered as a 20 minute infusion.

    Drug: AZD4604 for IV administration

  • Experimental
    Part 1b: AZD4604 for oral administration

    Healthy volunteers will receive a single PO dose of AZD4604.

    Drug: AZD4604 for oral administration

  • Experimental
    Part 2 (MAD): AZD4604 for inhalation via DPI (Dose 8)

    Healthy volunteers will receive multiple inhaled dose of AZD4604 administered with a DPI.

    Drug: AZD4604 for inhalation via DPI

  • Experimental
    Part 2 (MAD): AZD4604 for inhalation via DPI (Dose 9)

    Healthy volunteers will receive multiple inhaled dose of AZD4604 administered with a DPI.

    Drug: AZD4604 for inhalation via DPI

  • Experimental
    Part 2 (MAD): AZD4604 for inhalation via DPI (Dose 10)

    Healthy volunteers will receive multiple inhaled dose of AZD4604 administered with a DPI.

    Drug: AZD4604 for inhalation via DPI

  • Placebo comparator
    Part 2 (MAD): Placebo for AZD4604 for inhalation via DPI

    Healthy volunteers will receive placebo administered with a DPI.

    Drug: Placebo for AZD4604 for inhalation via DPI

  • Experimental
    Part 3 (MAD): AZD4604 for inhalation via DPI (Dose 9)

    Patients will receive multiple inhaled dose of AZD4604 administered with a DPI.

    Drug: AZD4604 for inhalation via DPI

  • Experimental
    Part 3 (MAD): AZD4604 for inhalation via DPI (Dose 10)

    Patients will receive multiple inhaled dose of AZD4604 administered with a DPI.

    Drug: AZD4604 for inhalation via DPI

  • Placebo comparator
    Part 3 (MAD): Placebo for AZD4604 for inhalation via DPI

    Patients will receive placebo administered with a DPI.

    Drug: Placebo for AZD4604 for inhalation via DPI

  • Experimental
    Part 3 (PoM): AZD4604 for inhalation via DPI (Dose 9 or Dose 10)

    Patients will receive multiple inhaled dose of AZD4604 administered with a DPI.

    Drug: AZD4604 for inhalation via DPI

Interventions

  • Healthy volunteers will receive AZD4604 administered with a DPI. The dose is expected to be administered between 10 to 45 minutes, depending upon dose. The dose will be administered after an overnight fast of at least 10 hours. Healthy volunteers will be allowed to drink water to prevent dehydration until 1 hour before dosing.

  • DrugPlacebo for AZD4604 for inhalation via DPI

    Part 1a: An additional cohort of healthy volunteers will receive a placebo administered with a DPI. Part 2: Healthy volunteers will receive placebo administered with a DPI. They will receive BID doses on Day 1 to Day 6, and a single dose will be administered on Day 7. Part 3: Patients will receive placebo administered with a DPI. They will receive BID doses on Day 1 to Day 9, and a single dose will be administered on Day 10.

  • Healthy volunteers will receive a single IV dose of AZD4604 administered over 20 minutes. The dose will be administered after an overnight fast of at least 10 hours. Healthy volunteers will be allowed to drink water to prevent dehydration until 1 hour before dosing.

  • Healthy volunteers will receive a single PO dose of AZD4604. The dose will be administered after an overnight fast of at least 10 hours. Healthy volunteers will be allowed to drink water to prevent dehydration until 1 hour before dosing.

  • Patients with mild asthma will also receive AZD4604 administered with a DPI. Patients will receive BID doses on Day 1 to Day 9 (morning and evening with 12-hour intervals between doses), and a single morning dose will be administered on Day 10. On Day 1 and Day 10, the morning dose will be administered after an overnight fast of 10 hours. For all other doses, the dose will be administered after a 1-hour fast.

06

What researchers measure

Primary outcomes

  1. Part 1a: Number of healthy volunteers with adverse events (AEs)

    Safety and tolerability of AZD4604 following inhaled administration of single ascending doses to healthy volunteers.

    Time frame: From screening (SAEs only) up to Final assessment (Day 7)

  2. Part 2: Number of healthy volunteers with AEs

    Safety and tolerability of AZD4604 following inhaled administration of multiple ascending doses to healthy volunteers.

    Time frame: From screening (SAEs only) up to Final assessment (Day 13)

  3. Part 1b: Maximum observed plasma (peak) drug concentration (Cmax)

    Cmax of AZD4604 following IV and PO administration of a single dose to healthy volunteers.

    Time frame: From Day 1 to Day 3

  4. Part 1b: Time to reach peak or maximum observed concentration or response following drug administration (tmax)

    tmax of AZD4604 following IV and PO administration of a single dose to healthy volunteers.

    Time frame: From Day 1 to Day 3

  5. Part 1b: Terminal rate constant, estimated by log linear least squares regression of the terminal part of the concentration time curve (λz)

    λz of AZD4604 following IV and PO administration of a single dose to healthy volunteers.

    Time frame: From Day 1 to Day 3

  6. Part 1b: Half life associated with terminal slope (λz) of a semi logarithmic concentration time curve (t1/2λz)

    t1/2λz of AZD4604 following IV and PO administration of a single dose to healthy volunteers.

    Time frame: From Day 1 to Day 3

  7. Part 1b: Partial area under the plasma concentration time curve from time 0 to time 12 (AUC [0 - 12])

    AUC (0 - 12) of AZD4604 following IV and PO administration of a single dose to healthy volunteers.

    Time frame: From Day 1 to Day 3

  8. Part 1b: Partial area under the plasma concentration time curve from time 0 to time 24 (AUC [0 - 24])

    AUC (0 - 24) of AZD4604 following IV and PO administration of a single dose to healthy volunteers.

    Time frame: From Day 1 to Day 3

  9. Part 1b: Area under the plasma concentration curve from zero to the last quantifiable concentration (AUClast)

    AUClast of AZD4604 following IV and PO administration of a single dose to healthy volunteers.

    Time frame: From Day 1 to Day 3

  10. Part 1b: Apparent total body clearance of drug from plasma after extravascular administration (CL/F)

    AUClast of AZD4604 following PO administration of a single dose to healthy volunteers.

    Time frame: From Day 1 to Day 3

  11. Part 1b: Total body clearance of drug from plasma after intravascular administration (CL)

    CL of AZD4604 following IV administration of a single dose to healthy volunteers.

    Time frame: From Day 1 to Day 3

  12. Part 1b: Volume of distribution (apparent) at steady state following extravascular administration (based on terminal phase) (Vz/F)

    Vz/F of AZD4604 following PO administration of a single dose to healthy volunteers.

    Time frame: From Day 1 to Day 3

  13. Part 1b: Volume of distribution following intravascular administration (based on terminal phase) (Vz)

    Vz of AZD4604 following IV administration of a single dose to healthy volunteers.

    Time frame: From Day 1 to Day 3

  14. Part 1b: Dose normalized AUClast, derived by AUClast divided by the dose administered (AUClast/D)

    AUClast/D of AZD4604 following IV and PO administration of a single dose to healthy volunteers.

    Time frame: From Day 1 to Day 3

  15. Part 1b: Area under plasma concentration-time curve from zero to infinity (AUCinf)

    AUCinf of AZD4604 following IV and PO administration of a single dose to healthy volunteers.

    Time frame: From Day 1 to Day 3

  16. Part 1b: Dose normalized AUCinf, derived by AUCinf divided by the dose administered (AUCinf/D)

    AUCinf/D of AZD4604 following IV and PO administration of a single dose to healthy volunteers.

    Time frame: From Day 1 to Day 3

  17. Part 1b: Dose normalized Cmax, derived by Cmax divided by the dose administered (Cmax/D)

    Cmax/D of AZD4604 following IV and PO administration of a single dose to healthy volunteers.

    Time frame: From Day 1 to Day 3

  18. Part 1b: Time of last observed (quantifiable) concentration (tlast)

    tlast of AZD4604 following IV and PO administration of a single dose to healthy volunteers.

    Time frame: From Day 1 to Day 3

  19. Part 3: Number of patients with AEs

    Safety and tolerability of AZD4604 following inhaled administration of multiple ascending doses to patients.

    Time frame: From Screening (SAEs only) up to Final Assessment (Day 16)

Secondary outcomes

  1. Part1b: Number of healthy volunteers with AEs

    Safety and tolerability of AZD4604 following IV and PO administration of a single dose to healthy volunteers.

    Time frame: From screening (only SAEs) to follow-up end of treatment visit (6 ± 1 day post-dose)

  2. Part 1a and Part 2: Cmax

    Cmax of AZD4604 following inhaled administration of single ascending doses and multiple ascending doses of AZD4604 to healthy volunteers.

    Time frame: From Day 1 to Day 7 (Part 1a) and from Day 1 to Day 13 (Part 2)

  3. Part 1a and Part 2: tmax

    tmax of AZD4604 following inhaled administration of single ascending doses and multiple ascending doses of AZD4604 to healthy volunteers.

    Time frame: From Day 1 to Day 7 (Part 1a) and from Day 1 to Day 13 (Part 2)

  4. Part 1a and Part 2: λz

    λz of AZD4604 following inhaled administration of single ascending doses and multiple ascending doses of AZD4604 to healthy volunteers.

    Time frame: From Day 1 to Day 7 (Part 1a) and on Day 7 (Part 2)

  5. Part 1a and Part 2: t1/2λz

    t1/2λz of AZD4604 following inhaled administration of single ascending doses and multiple ascending doses of AZD4604 to healthy volunteers.

    Time frame: From Day 1 to Day 7 (Part 1a) and on Day 7 (Part 2)

  6. Part1a: AUC (0 - 12)

    AUC (0 - 12) of AZD4604 following inhaled administration of single ascending doses of AZD4604 to healthy volunteers.

    Time frame: From Day 1 to Day 7

  7. Part 1a and Part 2: AUC (0 - 24)

    AUC (0 - 24) of AZD4604 following inhaled administration of single ascending doses and multiple ascending doses of AZD4604 to healthy volunteers.

    Time frame: From Day 1 to Day 7 (Part 1a) and on Day 7 (Part 2)

  8. Part 1a and Part 2: AUClast

    AUClast of AZD4604 following inhaled administration of single ascending doses and multiple ascending doses of AZD4604 to healthy volunteers.

    Time frame: From Day 1 to Day 7 (Part 1a) and from Day 1 to Day 13 (Part 2)

  9. Part 2: Area under plasma concentration-time curve in the dose interval (AUCτ)

    AUCτ of AZD4604 following inhaled administration of multiple ascending doses to healthy volunteers.

    Time frame: From Day 1 to Day 13

  10. Part 1a: AUCinf

    AUCinf of AZD4604 following administration of single ascending doses of AZD4604 to healthy volunteers.

    Time frame: From Day 1 to Day 7

  11. Part1a: AUCinf/D

    AUCinf/D of AZD4604 following inhaled administration of single ascending doses of AZD4604 to healthy volunteers.

    Time frame: From Day 1 to Day 7

  12. Part 1a and Part 2: CL/F

    CL/F of AZD4604 following inhaled administration of single and multiple ascending doses of AZD4604 to healthy volunteers.

    Time frame: From Day 1 to Day 7 (Part 1a) and on Day 7 (Part 2)

  13. Part 1a and Part 2: Vz/F

    Vz/F of AZD4604 following inhaled administration of single and multiple ascending doses of AZD4604 to healthy volunteers.

    Time frame: From Day 1 to Day 7 (Part 1a) and on Day 7 (Part 2)

  14. Part 1a and Part 2: AUClast/D

    AUClast/D of AZD4604 following inhaled administration of single and multiple ascending doses of AZD4604 to healthy volunteers.

    Time frame: From Day 1 to Day 7 (Part 1a) and from Day 1 to Day 13 (Part 2)

  15. Part 1a and Part 2: Cmax/D

    Cmax/D of AZD4604 following inhaled administration of single and multiple ascending doses of AZD4604 to healthy volunteers.

    Time frame: From Day 1 to Day 7 (Part 1a) and from Day 1 to Day 13 (Part 2)

  16. Part 1a and Part 2: tlast

    tlast of AZD4604 following inhaled administration of single and multiple ascending doses of AZD4604 to healthy volunteers.

    Time frame: From Day 1 to Day 7 (Part 1a) and from Day 1 to Day 13 (Part 2)

  17. Part 2: Dose normalized AUCτ, derived by AUCτ divided by the dose administered (AUCτ/D)

    AUCτ/D of AZD4604 following inhaled administration of multiple ascending doses to healthy volunteers.

    Time frame: From Day 1 to Day 13

  18. Part 2: Accumulation ratio for AUCτ (Rac AUC)

    Rac AUC of AZD4604 following inhaled administration of multiple ascending doses to healthy volunteers.

    Time frame: On Day 7

  19. Part 2: Accumulation ratio for Cmax (Rac Cmax)

    Rac Cmax of AZD4604 following inhaled administration of multiple ascending doses to healthy volunteers.

    Time frame: On Day 7

  20. Part 1b: Renal clearance of drug from plasma (CLR)

    CLR of AZD4604 following IV administration of a single dose to healthy volunteers.

    Time frame: From Day 1 to Day 2

  21. Part 1b: Cumulative amount of unchanged drug excreted into urine from time t1 to time t2 (Ae [t1 - t2])

    Ae (t1 - t2) of AZD4604 following IV administration of a single dose to healthy volunteers.

    Time frame: From Day 1 to Day 2

  22. Part 1b: Cumulative percentage of dose excreted unchanged in urine from time t1 to time t2 (fe [t1 - t2])

    Fe (t1 - t2) of AZD4604 following IV administration of a single dose to healthy volunteers.

    Time frame: From Day 1 to Day 2

  23. Part 2: Cough severity self-assessment (Visual analog scale)

    Effect of AZD4604 on cough severity in healthy will be evaluated volunteers when compared with placebo.

    Time frame: Day-1 to Day 7 (Pre-dose) and Day 8 (Post -dose)

  24. Part 3: Cmax

    Cmax of AZD4604 following inhaled administration of multiple ascending doses to patients.

    Time frame: From Days 1 to 16

  25. Part 3: AUCτ

    AUCτ of AZD4604 following inhaled administration of multiple ascending doses to patients.

    Time frame: From Days 1 to 16

  26. Part 3: AUC

    AUC of AZD4604 following inhaled administration of multiple ascending doses to patients.

    Time frame: From Days 1 to 16

  27. Part 3: Cough severity self-assessment (Visual analog scale)

    Effect of AZD4604 on cough severity in patients will be evaluated when compared with placebo.

    Time frame: From Day -3 to -1, and Days 1 to 10

  28. Part 3: Change from baseline in Fractional exhaled nitric oxide (FeNO) levels

    Fractional exhaled nitric oxide (FeNO) levels will be assessed.

    Time frame: From Day 1 to 10

07

Study locations

3 sites
  • Research Site
    Belfast, BT9 6AD, United Kingdom
  • Research Site
    Harrow, HA1 3UJ, United Kingdom
  • Research Site
    Manchester, M23 9QZ, United Kingdom
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please re-refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool. Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2022 to primary completion in Jan 2023, 6 months.

Of 173 industry-sponsored phase 1 interventional studies under Asthma, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 12. This study's 6 months is above that.

Counting every sponsor, half of 200 studies reached it within 6 months; a quarter within 3 and three quarters within 14.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 12, 2021
First posted
Feb 25, 2021
StartActual
Jul 8, 2022
Primary completionActual
Jan 24, 2023
CompletionActual
Jan 24, 2023
Last update
Mar 20, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 20, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04769869
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Feb 25, 2021
Start date
Jul 8, 2022
Primary completion
Jan 24, 2023
Completion
Jan 24, 2023
Last update
Mar 20, 2023

Study contacts

Dr Pablo Forte Soto
principal investigator · Parexel Early Phase Clinical Unit (London)
Rajkumar Chetty, Dr
principal investigator · Celerion
Dave Singh
principal investigator · Medicines Evaluation Unit
Jorg Taubel
principal investigator · Richmond Pharmacology Limited

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Londamocitinib

Start the discussion